Publication
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMelanomacivic_curation1.00
- drugUprosertibcivic_curation1.00
- geneAKT1civic_curation1.00
- geneBRAFcivic_curation1.00
- genePTENcivic_curation1.00
- variantAKT1 E17Kcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24735930
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AKT1 E17K + BRAF V600EAKT1BRAF2 | ||||||||
| Uprosertib | Melanoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID707A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study. PMID 24735930 · Lassen et al., 2014 · Open in CIViC | civic |
| Dabrafenib + UprosertibCombination | Melanoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID13115A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC | civic |
| BRAF V600E + PTEN LossBRAFPTEN2 | ||||||||
| Uprosertib | Melanoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID708Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC | civic |
| Dabrafenib + UprosertibCombination | Melanoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID13116Several BRAF V600E mutant melanoma cell lines (M249, M399, M397AR)) with PTEN mutation or loss of expression were among those sensitive to combination dabrafenib plus AKT inhibitor GSK2141795B, as mea… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC | civic |